• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025

    5/15/25 9:00:00 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care
    Get the next $RMD alert in real time by email

    SAN DIEGO and LONDON and DUBLIN and SYDNEY, May 15, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, has been named the Official Sleep Partner of the Qatar Airways British & Irish Lions Tour to Australia.

    The Tour brings rugby fans' dreams to life over a six-week period. For the first time in 12 years, The Lions squad, alongside an estimated 40,000 fans, will battle it out with the Wallabies, Super Rugby Pacific teams, and exhibition sides in six cities across Australia.

    As the Official Sleep Partner, Resmed will launch ‘Tackle Your Sleep,' a digital and content focused campaign featuring legendary rugby players. The campaign takes a light-hearted look at serious sleep health issues affecting players and the fans in Australia, the UK, and Ireland, with the rugby legends sharing advice and tools to support better sleep. The campaign aims to raise awareness about the importance of quality sleep for the rugby players and fans, as the third pillar of health, alongside exercise and diet1.

    Poor sleep can take a serious toll on mental health, physical health2, relationships3, and daily performance4. For athletes, it can impair optimal training, motivation, physical performance, and increase the risk of fatigue-related injuries3. A study of 175 rugby and cricket players found that half were classified as poor sleepers, with many reporting significant daytime fatigue5 — highlighting how sleep hygiene and recovery routines can offer a real competitive edge.

    Despite these known negative effects, Resmed's 2025 Global Sleep Survey found that one in four people globally are choosing to live with poor sleep6.

    Katrin Pucknat, Chief Marketing Officer of Resmed, said: "Poor sleep affects every aspect of our lives, but the good news is there are steps we can take to improve our sleep health.

    "As the Official Sleep Partner of the tour, we're excited to raise awareness about the powerful connection between sleep and athletic performance and inspire fans to think about the role that sleep plays in their own lives, while having some fun along the way."

    Ben Calveley, CEO of The British & Irish Lions said: "The Lions are always seeking new ways to support our players and management team and sleep is a vital component of performance.

    "Resmed adds another dimension to our acclimatisation and recovery strategies, ensuring the squad is primed to perform for the duration of the Tour. They will also be sharing insights to help travelling supporters stay well rested and in full voice for each fixture."

    Rugby Australia CEO, Phil Waugh said: "Resmed is a leader in their field and we're incredibly pleased to welcome them as an official partner for this year's British & Irish Lions Tour.

    "Quality sleep is certainly important for our players to perform at their best but there's no doubt good sleep is just as vital for all those celebrating and connecting throughout the Tour across Australia."

    The British & Irish Lions will play 10 matches in total, with three Test matches against the Wallabies in Brisbane, Melbourne, and Sydney.

    About The British & Irish Lions

    The British & Irish Lions is an iconic sporting brand in the world of rugby. Every four years, the Lions Men – the best of the best selected from England, Ireland, Scotland and Wales – travel to the southern hemisphere to take on Australia, New Zealand, or South Africa on landmark tours.

    The British & Irish Lions has announced the initial details of a historic inaugural Lions Women's Tour with the best women's players from England, Ireland, Scotland, and Wales traveling to New Zealand to play the current world champions in 2027. The British & Irish Lions will continue to collaborate with all key stakeholders, including its constituent Unions, World Rugby, and the various leagues to finalise full Tour details.

    The Lions is the pinnacle of players' careers, a once in a lifetime experience for fans and leaves an enduring legacy wherever the team visits. The Lions foundations are strong, built upon 130 years of history and tradition with tours taking place regularly since 1888.

    About Resmed

    Resmed (NYSE:RMD, ASX: RMD)) creates life-changing health technologies that people love. We're relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices, and intelligent software make home healthcare more personalized, accessible, and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we're redefining sleep health at resmed.com and follow @Resmed.

    For Media:

    Cassie-Anne Low, Resmed

    [email protected] 

    [email protected]

    For Investors:

    Mike Ott, Resmed

    [email protected]

    The 2025 British and Irish Lions Tour of Australia

    • Western Force v British & Irish Lions at 5:45pm AWST on Saturday 28 June at Optus Stadium, Perth
    • Queensland Reds v British & Irish Lions at 7:45pm AEST on Wednesday 2 July at Suncorp Stadium, Brisbane
    • New South Wales Waratahs v British & Irish Lions at 7:45pm AEST on Saturday 5 July at Allianz Stadium, Sydney
    • ACT Brumbies v British & Irish Lions at 7:45pm AEST on Wednesday 9 July at GIO Stadium, Canberra
    • AUNZ Invitational XV v British & Irish Lions at 7:15pm ACST on Saturday 12 July at Adelaide Oval, Adelaide
    • Wallabies v British & Irish Lions at 7:45pm AEST on Saturday July 19 at Suncorp Stadium, Brisbane
    • First Nations & Pasifika XV v British & Irish Lions at 7:45pm AEST on Tuesday 22 July at Marvel Stadium, Melbourne
    • Wallabies v British & Irish Lions at 7:45pm AEST on Saturday July 26 at Melbourne Cricket Ground, Melbourne
    • Wallabies v British & Irish Lions at 7:45pm AEST on Saturday August 2 at Accor Stadium, Sydney

    1 Stott D, Forde D, Sharma C, et al. Interactions with Nature, Good for the Mind and Body: A Narrative Review. Int J Environ Res Public Health. 2024;21(3):329. Published 2024 Mar 12. doi:10.3390/ijerph21030329he

    2 Lloyd-jones et al, Life's Essential 8: Updating and Enhancing the American Heart Association's Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association, Circulation 2022

    3 Gordon AM, Chen S. The role of sleep in interpersonal conflict: Do sleepless nights mean worse fights? Social Psychological and Personality Science. 2014;5(2):168–175

    4 Perry GS, Patil SP, Presley-Cantrell LR. Raising awareness of sleep as a healthy behavior. Prev Chronic Dis. 2013

    5 Swinbourne R, Gill N, Vaile J, Smart D. Prevalence of poor sleep quality, sleepiness and obstructive sleep apnoea risk factors in athletes. Eur J Sport Sci. 2016 Oct;16(7):850-8. doi: 10.1080/17461391.2015.1120781. Epub 2015 Dec 23. PMID: 26697921.

    6 Resmed's 2025 Global Sleep Survey



    Primary Logo

    Get the next $RMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RMD

    DatePrice TargetRatingAnalyst
    7/16/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    7/15/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    3/19/2025$280.00Overweight
    Morgan Stanley
    3/19/2025Overweight
    Morgan Stanley
    1/16/2025Buy
    Goldman
    1/10/2025$252.00Neutral
    Piper Sandler
    12/13/2024$250.00Hold
    Stifel
    9/24/2024$280.00Outperform
    Robert W. Baird
    More analyst ratings

    $RMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Product Officer Leong Justin was granted 5,462 units of ReMed Common Stock, increasing direct ownership by 25% to 27,180 units (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    8/19/25 3:29:06 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Sandercock Brett was granted 5,462 units of ResMed Common Stock, increasing direct ownership by 7% to 88,745 units (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    8/19/25 2:50:03 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Farrell Michael J. was granted 12,289 units of ResMed Common Stock, increasing direct ownership by 3% to 467,792 units (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    8/19/25 2:28:50 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    SEC Filings

    View All

    SEC Form 8-K filed by ResMed Inc.

    8-K - RESMED INC (0000943819) (Filer)

    8/18/25 4:20:28 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by ResMed Inc.

    10-K - RESMED INC (0000943819) (Filer)

    8/7/25 8:44:48 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by ResMed Inc.

    8-K - RESMED INC (0000943819) (Filer)

    7/31/25 6:30:21 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ResMed upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded ResMed from Sector Perform to Outperform and set a new price target of $294.00

    7/16/25 7:50:57 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    ResMed upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded ResMed from Sector Perform to Outperform and set a new price target of $294.00

    7/15/25 8:29:55 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Morgan Stanley initiated coverage on ResMed with a new price target

    Morgan Stanley initiated coverage of ResMed with a rating of Overweight and set a new price target of $280.00

    3/19/25 10:13:23 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awards and 10,000 Patents and Designs

    SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced that its AirTouch™ N30i nasal cradle mask won two prestigious Red Dot Awards: Product Design 2025 in both the Innovative Products and Medical Design & Healthcare categories. The AirTouch N30i features Resmed's first-ever nasal cushion made from fabric fused with silicone, designed to deliver both clinical performance and a therapy experience that feels more natural and comfortable making it easier for people to start and stick with CPAP therapy. Launched in October 2024, the AirTouch N30i builds on

    8/21/25 9:00:00 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio

    Mowad-Nassar is Senior Vice President at AbbVie and President, Specialty and U.S. Therapeutics Operations Her appointment brings over 30 years of strategic, commercial, and operational expertise in the pharmaceutical and broader healthcare industry, with a focus on digital innovation SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company also announced that board member Rich Sulpizio is thanked for two decades of contributions to Resmed, and will retire from the board, not standing for reelection at the 2025 Annual Meeting of Stockholders, scheduled fo

    8/18/25 4:15:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025

    Year-over-year revenue grows 10%, operating profit up 19%, non-GAAP operating profit up 19%Operating cash flow of $539 millionQuarterly dividend increases 13% to $0.60 per share Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended June 30, 2025. Fourth Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 10% to $1.3 billion; up 9% on a constant currency basis Gross margin improved 230 bps to 60.8%; non-GAAP gross margin improved 230 bps to 61.4

    7/31/25 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Leadership Updates

    Live Leadership Updates

    View All

    Resmed Names Salli Schwartz as Chief Investor Relations Officer

    SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she

    4/21/25 5:00:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Jan De Witte joins GHO Capital as Operating Partner

    Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

    2/11/25 4:30:00 AM ET
    $IART
    $RMD
    Medical/Dental Instruments
    Health Care

    Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

    NEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines today announced the appointment of Alison Wimms, Ph.D. as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent ResMed. Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, and Master of Medicine (Sleep Medicine) and Bachelor of Science degrees from the University of Sydney. "Incannex's

    2/4/25 9:15:00 AM ET
    $IXHL
    $RMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $RMD
    Financials

    Live finance-specific insights

    View All

    Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025

    Year-over-year revenue grows 10%, operating profit up 19%, non-GAAP operating profit up 19%Operating cash flow of $539 millionQuarterly dividend increases 13% to $0.60 per share Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended June 30, 2025. Fourth Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 10% to $1.3 billion; up 9% on a constant currency basis Gross margin improved 230 bps to 60.8%; non-GAAP gross margin improved 230 bps to 61.4

    7/31/25 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025

    SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, July 31, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:  •Location:https://investor.resmed.com •Date:Thursday, July 31, 2025 •Time:1:30 p.m. PDT / 4:30 p.m. EDT •International:London, Thursday, July 31, 2025, 9:30 p.m. BSTSydney, Friday, August 1, 2025, 6:30 a.m. AEST     Please note, Resmed

    7/1/25 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Acquires VirtuOx

    SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed's commitment to improving the way care is delivered—by making it more accessible, more coordinated, and more patient friendly. With VirtuOx's at-home diagnostic services, Resmed will be better positioned to support patients earlier in their journey and help healthcare providers and homecare companies deliver care in a simpler, more connected wa

    5/1/25 9:00:00 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/23 1:36:52 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/22 5:05:17 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/22 8:32:59 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care